DF/HCC Program Affiliation

Gastrointestinal Malignancies
Translational Pharmacology and Early Therapeutic Trials

DF/HCC Associations

Director, Protocol Review and Monitoring System
Medical Director, Clinical Trials Operations, Executive Committee
Acting Director, Clinical Research Support
Member, Clinical Science Coordinating Committee
Member, Center Scientific Council

Research Abstract

The major area of my research focus is in the evaluation of new agents and approaches in phase I, pilot and early phase II trials. This includes the evaluation of pharmacokinetics and biological correlates of the activity of these agents or approaches. I am especially interested in the development of new theraputic approaches for gastrointestestional malignancies. I have an interest in designing and implementing systems to improve the quality and performance of clinical trials. This includes the development and utlization of computerized systems whenever possible.

Publications

• Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tu
  17470685
• Jain RK, Duda DG, Clark JW, Loeffler JS.Lessons from phase III clinical trials on anti-VEGF therapy for cancer.Nat Clin Pract Oncol 2006 Jan;3(1):24-40.
  16407877
• Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ.Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.Clin Cancer Res 2005 Aug 1;11
  16061863